Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

mCRPC: Alternative starting points

Noel Clarke

12 mCRPC: Alternative starting points - Noel Clarke

Professor Noel W Clarke, Salford Royal Hospital and The Christie, Manchester, continues with his case report of a 58 year old man with asymptomatic adenocarcinoma of the prostate (cT3 Gleason) treated initially with androgen ablation monotherapy followed by 6 cycles of androgen deprivation therapy (ADT) and docetaxel (with G-CSF). The prostate-specific antigen nadir response was 1.3 ng/ml. The audience is asked to vote for treatment with ADT alone, ADT plus bicalutamide, novel androgen targeting agents or rechallenge with docetaxel.